Published in Hepatitis Weekly, May 1st, 2006
Study 1: A study from the United States has chronicled virologic and enzymatic studies that revealed the mechanism of K65R- and Q151M-associated human immunodeficiency virus (HIV)-1 drug resistance towards emtricitabine (FTC) and lamivudine (3TC).
"FTC and 3TC are deoxycytidine analogues with potent and selective inhibition of HIV and hepatitis B virus (HBV) replication. The K65R mutation in the HIV reverse transcriptase (RT) confers reduced susceptibility to 3TC, ddC, ddI, abacavir, and tenofovir in vitro," wrote J.Y. Feng and colleagues, Gilead Science Inc.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.